[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-weight-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-weight-management":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,66,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100650045","phase-3-a-study-of-once-daily-oral-asc30-to-evaluate-the-efficacy-and-safety-in-adult-participants-with-obesity-or-overweight-with-type-2-diabetes-100650045",false,"NCT07743450","A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes","A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)","AURORA-2","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.\n2. Have a BMI ≥ 27 kg\u002Fm2 at screening.\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n4. Have a diagnosis of T2D according to the WHO classification or other locally applicable standards, with HbA1c \\> 6.5% (48 mmol\u002Fmol) to ≤10.5% (91 mmol\u002Fmol) at screening.\n\nExclusion Criteria:\n\n1. Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar state\u002Fcoma, or any other types of diabetes except T2DM.\n2. Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening.\n3. Have an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73 m2, as determined by the laboratory at screening.\n4. Have a history of acute or chronic pancreatitis any time prior to screening.\n5. Have known allergies or intolerance to glucagon-like peptide-1 Receptor Agonists (GLP-1 RA).\n6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\n7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.","ALL","18 Years",{"count":20,"type":21},1560,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.",[27,28,29,30],"Obesity","Overweight","Chronic Weight Management","Type 2 Diabetes Mellitus",[27,28,32],"Type 2 Diabetes","RECRUITING","2026-08-12",{"date":36,"type":37},"2026-08-14","ACTUAL",{"date":39,"type":21},"2026-08",{"date":41,"type":21},"2028-07",{"name":43,"class":44},"Ascletis Pharma (China) Co., Limited","INDUSTRY",136,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":64,"locationsCount":65},"100649973","phase-3-a-study-of-once-daily-oral-asc30-to-evaluate-the-efficacy-and-safety-in-adult-participants-with-obesity-or-overweight-with-weight-related-comorbidities-100649973","NCT07743463","A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities","A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)","AURORA-1","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.\n2. Have a BMI ≥ 30 kg\u002Fm2 or a BMI ≥ 27 kg\u002Fm2 and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening:\n\n   * Hypertension\n   * Dyslipidemia\n   * Obstructive sleep apnea\n   * Cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure).\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state\u002Fcoma. Participants with a history of gestational diabetes are eligible to participate in this trial.\n2. Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening.\n3. Have an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73 m2, as determined by the laboratory at screening.\n4. Have a history of acute or chronic pancreatitis any time prior to screening.\n5. Have known allergies or intolerance to other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs.\n6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\n7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.",{"count":55,"type":21},3003,[24],"Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.",[27,28,29],[27,28,60],"Weight Management",{"date":36,"type":37},{"date":39,"type":21},{"date":41,"type":21},{"name":43,"class":44},120,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100641707","efficacy-and-safety-of-aleniglipron-in-participants-with-obesity-or-overweight-with-a-weight-related-comorbidity-accomplish-1-100641707","NCT07654361","Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)","A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity","Inclusion Criteria:\n\n* Signed informed consent\n* BMI ≥30 kg\u002Fm2 (obese) or BMI ≥27 kg\u002Fm2 (overweight) and presence of ≥1 of the obesity related comorbidities.\n\nExclusion Criteria:\n\n* Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.\n* Self-reported change in body weight \\>5 kg within 3 months before Screening.\n* Have prior or planned surgical or non-surgical treatment for obesity.\n* Have or plan to have endoscopic and\u002For device-based therapy for obesity.\n* Have obesity induced by other endocrine disorders.\n* Impaired renal function at Screening\n* Chronic malabsorption","79 Years",{"count":75,"type":21},3600,[24],"Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.",[27,28,29],[27,28,80,81,82,83,84,85,86],"GSBR-1290","Aleniglipron","Chronic weight management","Obese","Small molecule","GLP-1","Structure Therapeutics","2026-08-07",{"date":89,"type":37},"2026-08-10",{"date":91,"type":37},"2026-07-13",{"date":93,"type":21},"2028-11",{"name":95,"class":44},"Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics",71,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":123,"locationsCount":124},"100641426","a-study-of-aleniglipron-in-adults-with-obesity-or-overweight-and-type-2-diabetes-mellitus-accomplish-2-100641426","NCT07654374","A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)","A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)","Inclusion Criteria:\n\n* Signed Informed Consent\n* Have a BMI ≥27.0 kg\u002Fm2 at Screening\n* Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol\u002Fmol) to ≤10% (86 mmol\u002Fmol) at Screening\n\nExclusion Criteria:\n\n* Have type 1 diabetes, history of ketoacidosis or hyperosmolar state\u002Fcoma, or any other types of diabetes except T2DM.\n* Have had 1 or more episode of severe hypoglycemia and\u002For 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.\n* Are currently receiving or planning to receive treatment for diabetic retinopathy and\u002For macular edema\n* Self-reported change in body weight \\>5 kg (11 pounds) within 3 months before Screening.\n* Have prior or planned surgical or non-surgical treatment for obesity.",true,{"count":106,"type":21},1100,[24],"This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.",[27,28,29,110],"Type2 Diabetes Mellitus",[112,113,80,114,115,116,117,118,85,86],"obesity","overweight","aleniglipron","chronic weight management","obese","type 2diabetes mellitus","small molecule",{"date":89,"type":37},{"date":121,"type":37},"2026-07-17",{"date":93,"type":21},{"name":95,"class":44},74]